Sildenafil Actavis
sildenafil
Table of contents
Overview
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Authorisation details
| Product details | |
|---|---|
| Name |
Sildenafil Actavis
|
| Agency product number |
EMEA/H/C/001090
|
| Active substance |
sildenafil
|
| International non-proprietary name (INN) or common name |
sildenafil
|
| Therapeutic area (MeSH) |
Erectile Dysfunction
|
| Anatomical therapeutic chemical (ATC) code |
G04BE03
|
Generic |
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines. |
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Actavis Group PTC ehf
|
| Revision |
15
|
| Date of issue of marketing authorisation valid throughout the European Union |
10/12/2009
|
| Contact address |
Reykjavíkurvegur 76 - 78
IS-220 Hafnarfjörður Iceland |
Product information
27/06/2022 Sildenafil Actavis - EMEA/H/C/001090 - IB/0023
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Urologicals
Therapeutic indication
Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.
In order for Sildenafil Actavis to be effective, sexual stimulation is required.